Starting
Initialising…
0%
ERBB3
Final classification
VUS
ERBB3 c.1008_1010inv · p.Gly337Gln
ERBB3

NM_001982.3:c.1008_1010delTGGinsCCA (p.Gly337Gln) in ERBB3 was assessed using the generic ACMG/AMP 2015 framework (PMID:25741868).

Gene
ERBB3
Transcript
NM_001982.3
HGVS · transcript:coding
NM_001982.3:c.1008_1010inv
Consequence
N/A
GRCh38
chr12:56088767 TGG>CCA
GRCh37
chr12:56482551 TGG>CCA
Basis gene-specific framework lacked a usable explicit final combination framework, so generic ACMG/AMP 2015 final-combination rules were applied as fallback; applied criteria: PM2 supporting; combination = 1 supporting, which maps to VUS.
gene-specific framework lacked a usable explicit final combination framework, so generic ACMG/AMP 2015 final-combination rules were applied as fallback; applied criteria: PM2 supporting; combination = 1 supporting, which maps to VUS.
Classification rationale
PM2 VUS
ERBB3 c.1008_1010inv

NM_001982.3:c.1008_1010delTGGinsCCA (p.Gly337Gln) in ERBB3 was assessed using the generic ACMG/AMP 2015 framework (PMID:25741868).1 PVS1 is not applicable: the variant produces a single missense substitution, not a null variant in a gene where loss of function is a known disease mechanism.2 The variant is absent from gnomAD v2.1, v4.1, and gnomAD-Canada (allele frequency 0.0). PM2 is met at supporting strength.3 The variant is absent from ClinVar with no functional data, no de novo observations, no case-control studies, no segregation data, and no in silico scores applicable. All other criteria are not met, not applicable, or not assessed.4 With only PM2_supporting met, the variant is classified as a Variant of Uncertain Significance (VUS) under generic ACMG/AMP 2015 combination rules.5

PM2 VUS
1 generic_acmg_combination_rules
5 generic_acmg_combination_rules
Gene diagram · NM_001982.3 · variants mapped to exon structure
ERBB3 NM_001982.3
Fetching transcript structure from UCSC…
Applied criteria · 1 met · select any tile
Met
Not met
Not assessed
N/A
Strength very strong supporting
Pathogenic evidence
PVS
PS
PM
PP
Benign evidence
BA
BS
BP
Rationale
Select a criterion.
Sources
Evidence used
    Gaps remaining
      Rule
      Research & evidence
      Population frequency
      gnomAD v4.1 screenshot
      gnomAD v4.1
      gnomAD v2.1 screenshot
      gnomAD v2.1
      Population frequency
      Absent from gnomAD v4.1.
      Absent from gnomAD v2.1.
      Absent from gnomAD-Canada v1.0.
      ClinVar screenshot
      ClinVar
      This variant is absent from ClinVar.
      SpliceAI screenshot
      In silico
      SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01).
      Functional / OncoKB screenshot
      Functional Unknown Oncogenic Effect
      OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. ERBB3, a receptor tyrosine kinase, is altered by mutation or amplification in various cancer types.
      OncoKB ↗
      COSMIC screenshot
      COSMIC
      Cancer hotspots screenshot
      Cancer hotspots
      Somatic evidence Hotspot
      COSMIC
      This variant lies in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).
      Hotspots
      This variant lies in a statistically significant hotspot.
      Sources & reference links
      8Sources
      ClinVar
      gnomAD v2.1
      gnomAD v4.1
      gnomAD-Canada
      SpliceAI
      OncoKB
      COSMIC
      Cancer hotspots